Great I am finishing my first month of these injections and I have lost 4 lbs so far
The phase 2 signal that put retatrutide on the map The pivotal early evidence is the phase 2 trial published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity to escalating retatrutide doses or placebo over 48 weeks
Major Findings: Developed LY3437943 (retatrutide), a novel triple agonist targeting the GLP-1, GIP, and glucagon receptors
Others note the potential for retatrutide, if cleared, to make its way onto obesity treatment guidelines, particularly if studies identify comparable or higher effects
At 20mg/mL, a 1mg dose requires only 5 units on the syringe, which is a tiny mark and extremely easy to misread
The cagrilintide injection is administered subcutaneously, once weekly, at any time of day regardless of meals